靶向髓源性抑制细胞的叶酸循环增强肿瘤免疫治疗效果研究
Targeting folate cycle enhances effects of cancer immunotherapy by modulating myeloid-derived suppressor cells
Note： A. MC38 tumor burden assessed by gross visualization. B. Tumor weight of MC38 tumor-bearing mice in pemetrexed-treated group. C. Tumor growth curve of MC38 tumor-bearing mice in pemetrexed-treated group. D/G. After combination of anti-CD8 monoclonal antibody and Pemetrexed treatment, MC38 tumor burden(D) was assessed by gross visualization, and tumor growth curve (G) was drawn. E/H. After combination of anti-Gr1 monoclonal antibody and Pemetrexed treatment, MC38 tumor burden(E) was assessed by gross visualization, and tumor growth curve (H) was drawn. F/I. After combination of anti-PD-1 monoclonal antibody and Pemetrexed treatment, MC38 tumor burden(F) was assessed by gross visualization, and tumor growth curve (I) was drawn. J/K.After combination of anti-PD-1 monoclonal antibody and Pemetrexed treatment, LLC tumor burden (J) was assessed by gross visualization, and tumor growth curve(K) was drawn.①P=0.009, ②P=0.029, ③P=0.001, compared with the control group. ④P=0.000, compared with the control group, combination of anti-CD8 monoclonal antibody and Pemetrexed group, combination of anti-Gr1 monoclonal antibody and Pemetrexed group, or combination of anti-PD-1 monoclonal antibody and Pemetrexed group.
